Stoke Therapeutics Inc. (STOK) News

Stoke Therapeutics Inc. (STOK): $23.23

0.60 (+2.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add STOK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

Filter STOK News Items

STOK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

STOK News Highlights

  • STOK's 30 day story count now stands at 12.
  • Over the past 17 days, STOK's stories per day has been in a clear downtrend, falling by about 2.00 per 8 days.
  • The most mentioned tickers in articles about STOK are RNA, ABIO and ADVM.

Latest STOK News From Around the Web

Below are the latest news stories about Stoke Therapeutics Inc that investors may wish to consider to help them evaluate STOK as an investment opportunity.

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug...

Benzinga | October 8, 2021

Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference on Tuesday, September 28, 2021, at 4:00 p.m. ET. A live audio webcast of the presentation, which will be conducted in fireside chat format, wi

Business Wire | September 22, 2021

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote

Business Wire | September 21, 2021

Stoke Therapeutics Posts Encouraging Interim Safety Data From Early-Stage Dravet Syndrome Trial

Stoke Therapeutics Inc (NASDAQ: STOK) announced interim analysis data from Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome. The interim analysis is based on data from 21 patients who were treated in the single 10mg (n=5), 20mg (n=4), or 30mg (n=6) dose cohorts. A dose-proportional increase in study drug exposure was observed in plasma pharmacokinetics. Cerebrospinal fluid (CSF) exposure was measurable up to six months following a single intrathecal dose. A do

Yahoo | September 21, 2021

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | September 13, 2021

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

BEDFORD, Mass., August 10, 2021--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2021 and provided business updates.

Yahoo | August 10, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences in August

BEDFORD, Mass., August 03, 2021--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences in August.

Yahoo | August 3, 2021

Canaccord Genuity Stick to Their Buy Rating for Stoke Therapeutics Inc By Investing.com

Canaccord Genuity Stick to Their Buy Rating for Stoke Therapeutics Inc

Investing.com | June 30, 2021

Stoke Therapeutics started at neutral with $35 stock price target at UBS

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

MarketWatch | May 18, 2021

Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021, at 5:00 p.m. ET.

BioSpace | May 17, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6681 seconds.